map of conference rooms https://www.downing-conferences-cambridge.co.uk/assembly-room
|09:00 to 09:30||Registration and Refreshments
Drawing Room, Howard Building
|09:30 to 09:35||Welcome
Dr Vik Selvarajah (Clinical Lecturer) and Dr Joseph Cheriyan (Consultant Clinical Pharmacologist & EMI Training Lead), Division of Experimental Medicine & Immunotherapeutics
|09:35 to 10:05||Overview of Drug Development in Chronic Kidney Disease (CKD)
Dr Rona Smith, Clinical Lecturer, University of Cambridge & Honorary NHS Consultant, Nephrology Cambridge University Hospitals Trust.
|10:05 to 10:35||Phase 3 trials- reasons for lack of success (via Video TC)
Dr Phil Ambery, Global Clinical Leader, Diabetes, AstraZeneca AB, Gothenburg
|10:35 to 11:05||Pre-clinical development -
Challenges in predicting human dose-response for CKD treatments
Dr Christine Ahlström, Modelling & Simulation team leader, Gothenburg, AstraZeneca
|11:05 to 11:20||BREAK|
|11:20 to 11:50||Recent developments in whole exome sequencing in CKD & potential for future target identification in CKD
Dr Slavé Petrovski Vice-president and Head of Genome Analytics, AstraZeneca Centre for Genomics Research (CGR), Cambridge
|11:50 to 12:20||Research and advances on the treatment of Hyperkalemia
Dr Carol Moreno Senior Global Medical Affairs Lead, Astrazeneca Dr Toby Humphrey Clinical research fellow, department of medicine, University of Cambridge
|12:20 to 13:30||LUNCH|
|13:30 to 14:00||Identifying therapeutic targets in immune-mediated kidney disease
Dr Menna Clatworthy Reader in Immunity and Inflammation, Department of Medicine, University of Cambridge, UK; Honorary Consultant Nephrologist, Cambridge University NHS Foundation Trust
|14:00 to 14:30||T cell involvement in diabetic nephropathy & proteinuric renal disease: Abatacept (CTLA4-Ig) as a case study
Dr Lutz Jermutus, Senior Director, R&D, Product Development Team Leader Cardiovascular, Renal and Metabolism iMED, BioPharmaceuticals R&D, AstraZeneca. Industrial Fellow & Graduate Mentor Trinity Hall, University of Cambridge.
|14:30 to 15:10||Break out groups
CTLA-4: Re-purposing in CKD
Dr Victoria Parker, Director of Clinical Development in CVRM (CV, renal and metabolism), AstraZeneca & Honorary consultant endocrinologist, Cambridge University Hospitals Trust
|15:10 to 15:30||BREAK|
|15:30 to 16:00||Kidney organ culture models for studying human disease
Professor John Bradley, Consultant Renal Physician and National Institute for Health Research Cambridge Biomedical Research Centre, and Director of Research for Cambridge University Health Partners
|16:00 to 16:30||Belimumab – A phase 2 clinical trial in Renal Transplantation
Dr Shaun Flint, Early Development Leader at GlaxoSmithKline and a physician with nephrology and vasculitis experience
|16:30 to 17:00||Clinical Trials in Nephrology - Challenges and Opportunities
Dr Thomas Hiemstra, Honorary consultant nephrologist, Cambridge University Hospitals Trust & trials methodologist, Cambridge Clinical Trials Unit
|17:00 to 17:15||Conclusion|
|17:15 to 19:00||Networking with refreshments|
|19:00 to 22:30||Dinner|
Downing College, Regent Street, Cambridge, CB2 1DQ
Cancer Drug Discovery and Development
To understand cancer drug discovery and development through a range of lectures, panel discussions and case studies....
Renal Drug Discovery and Development
map of conference rooms https://www.downing-conferences-cambridge.co.uk/assembly-room ...
Advancing Research in Renal Autoimmunity - A Collaborative Symposium for Industry and Academia
Dinner is now full and there are a few remaining spaces for daytime attendance.
Hosted by the UK Kidney Research Consortium (UKKRC), Glomerulonephritis Clinical Study Group (GN CSG) in partnership with the Experimental Medicine Initiative, University of ...